`
`
` NDA 202107/S-008
`
`
`
`
`
`
`
` SUPPLEMENT APPROVAL
`
`
` Corcept Therapeutics
`
` Attention: Susan Rinne
`
` Vice President, Corporate Regulatory Affairs
`
` 149 Commonwealth Drive
`
` Menlo Park, CA 94025
`
`
`
`
`Dear Ms. Rinne:
`
`
`
`
`
`
`Please refer to your supplemental new drug application (sNDA) dated and received
`
`
`
`
`March 30, 2018, and your amendments, submitted pursuant to section 505(b)(2) of the
`
`
`
`
`
`Federal Food, Drug, and Cosmetic Act (FDCA) for Korlym (mifepristone) tablets, 300 mg.
`
`
`
`
`
`This Prior Approval supplemental new drug application provides for the revisions to the
`
`
`
`
`
`prescribing information (PI) to include the results from Study C1073-38 titled, A Phase 1, Open-
`
`
`
`
`Label, Drug-drug Interaction Study in Healthy Subjects to Determine the Effects of a Strong
`
`Inhibitor (ltraconazole) of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites.
`
`
`
`
`
`
`Specific sections of the PI impacted by this information are:
`
`
`
`
`
`1. Dosage and Administration section, 2.4 Concomitant Administration with CYP3A4
`
`Inhibitors subsection,
`
`
`
`
`
`
`2. Warnings and Precautions section, 5.6 Use of Strong CYP3A4 inhibitors subsection
`
`
`
`
`
`3. Drug Interactions section, 7.2 CYP3A4 Inhibitors subsection
`
`
`
`4. Clinical Pharmacology section, 12.3 Pharmacokinetics subsection
`
`
`
`
`The supplement also provides for revisions to the PI to comply with the Pregnancy Lactation
`
`Labeling Rule (PLLR).
`
`
`The Medication Guide (MG) has also been revised to be consistent with the PLLR revisions to
`
`the PI and other editorial revisions.
`
`
`APPROVAL & LABELING
`
`
`
`We have completed our review of this application, as amended. It is approved, effective on the
`
`
`
`date of this letter, for use as recommended in the enclosed agreed-upon labeling.
`
`
`CONTENT OF LABELING
`
`As soon as possible, but no later than 14 days from the date of this letter, submit the content of
`
`
`
`
`
`
`labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA
`
`
`
`
`automated drug registration and listing system (eLIST), as described at FDA.gov.1 Content of
`
`
`
`
`
`labeling must be identical to the enclosed labeling (text for the Prescribing Information, and
`
`Medication Guide), with the addition of any labeling changes in pending “Changes Being
`
`
` 1 http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
`
`
`
`Reference ID: 4516016
`
`

`

`
`
`
`
`
`
`
`
`
`
`
` NDA 202107/S-008
` Page 2
`
`
`
` Effected” (CBE) supplements, as well as annual reportable changes not included in the
`
`enclosed labeling.
`
` Information on submitting SPL files using eList may be found in the guidance for industry SPL
`
` Standard for Content of Labeling Technical Qs and As.2
`
`
`
`
`The SPL will be accessible from publicly available labeling repositories.
`
`
`
`
`Also within 14 days, amend all pending supplemental applications that include labeling changes
`
`
`for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with
`
`
`
`
`
`
`the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the
`
`
`changes approved in this supplemental application, as well as annual reportable changes. To
`
`
`facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all
`
`changes, as well as a clean Microsoft Word version. The marked-up copy should provide
`
`
`
`appropriate annotations, including supplement number(s) and annual report date(s).
`
`
`
`REQUIRED PEDIATRIC ASSESSMENTS
`
`Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new
`
`
`
`
`active ingredients (which includes new salts and new fixed combinations), new indications, new
`
`
`
`
`
`dosage forms, new dosing regimens, or new routes of administration are required to contain an
`
`assessment of the safety and effectiveness of the product for the claimed indication in pediatric
`
`
`
`
`patients unless this requirement is waived, deferred, or inapplicable.
`
`
`
`Because none of these criteria apply to your application, you are exempt from this requirement.
`
`
`
`
`
`
`
`PROMOTIONAL MATERIALS
`
`
`You may request advisory comments on proposed introductory advertising and promotional
`
`
`labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory
`
`
`
`
`
`
`comments, (2) the proposed materials in draft or mock-up form with annotated references, and
`
`
`
`
`(3) the Prescribing Information to:
`
`
`
`
`
`
`
`
`OPDP Regulatory Project Manager
`
`Food and Drug Administration
`
`Center for Drug Evaluation and Research
`
`
`Office of Prescription Drug Promotion (OPDP)
`
`5901-B Ammendale Road
`
`Beltsville, MD 20705-1266
`
`
`
`Alternatively, you may submit a request for advisory comments electronically in eCTD format.
`
`
`
`For more information about submitting promotional materials in eCTD format, see the draft
`
`
`
`
`
`
`
`
` 2 We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance
` Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.
`
`
`
`
`
`U.S. Food and Drug Administration
`
`Silver Spring, MD 20993
`
`www.fda.gov
`
`
`
`
`
`Reference ID: 4516016
`
`

`

`
`
`
`
`
` NDA 202107/S-008
` Page 3
`
`
`
` Guidance for industry Providing Regulatory Submissions in Electronic and Non-Electronic
`
`
`
` Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs.3
`
`
`
`
`
`You must submit final promotional materials and Prescribing Information, accompanied by a
`
`
`
`
`Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form
`
`FDA 2253 is available at FDA.gov.4 Information and Instructions for completing the form can be
`
`
`
`
`
`
`
`found at FDA.gov.5 For more information about submission of promotional materials to the
`
`Office of Prescription Drug Promotion (OPDP), see FDA.gov.6
`
`
`REPORTING REQUIREMENTS
`
`We remind you that you must comply with reporting requirements for an approved NDA
`
`
`
`(21 CFR 314.80 and 314.81).
`
`
`
`If you have any questions, call Jennifer Johnson, Regulatory Project Manager, at 301-796-2194.
`
`
`
`
`
`
`Sincerely,
`
`
`{See appended electronic signature page}
`
`
`Lisa B. Yanoff, MD
`
`Director (Acting)
`
`Division of Metabolism and Endocrinology Products
`
`Office of Drug Evaluation II
`
`Center for Drug Evaluation and Research
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`ENCLOSURES:
`
`• Content of Labeling
`
`
`
`o Prescribing Information
`
`
`o Medication Guide
`
`
`
`
`
`
`
`
`
`
`
`
`
` 3 When final, this guidance will represent the FDA’s current thinking on this topic. For the most recent
` version of a guidance, check the FDA guidance web page at
`
` https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.
`
`4 http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf
`
`
`
` 5 http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf
`
`
` 6 http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm
`
`
`
`
`U.S. Food and Drug Administration
`
`Silver Spring, MD 20993
`
`www.fda.gov
`
`
`
`Reference ID: 4516016
`
`

`

`Signature Page 1 of 1
`--------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically. Following this are manifestations of any and all
`electronic signatures for this electronic record.
`--------------------------------------------------------------------------------------------
`/s/
`------------------------------------------------------------
`
`LISA B YANOFF
`11/05/2019 03:05:54 PM
`
`Reference ID: 4516016
`
`